"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26078429.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3183.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HER2-targeted therapy has moved beyond trastuzumab to include other monoclonals targeting the cell surface, receptor tyrosine kinase inhibitors of HER2, and antibody-drug conjugates. Afatinib, a small molecule receptor tyrosine kinase inhibitor, now joins the ranks of HER2-targeting agents in combination with trastuzumab. The combination brings new opportunities and challenges.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Erb-b2 Receptor Tyrosine Kinases